Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.

Official Title

A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

Keywords

Acute Ischemic Stroke Transient Ischemic Attack (TIA) Stroke Ischemic Stroke Ischemic Attack, Transient Ischemia Aspirin Clopidogrel BMS-986177 Dose 1: BMS-986177 + Aspirin + Clopidogrel Dose 2: BMS-986177 + Aspirin + Clopidogrel Dose 3: BMS-986177 + Aspirin + Clopidogrel Dose 4: BMS-986177 + Aspirin + Clopidogrel Dose 5: BMS-986177 + Aspirin + Clopidogrel Dose 6: BMS-986177 + Aspirin + Clopidogrel Dose 7: BMS-986177 + Aspirin + Clopidogrel

Eligibility

For people ages 40 years and up

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Male and Female ≥40 years of age
  • Acute Ischemic Stroke or Transient Ischemic Attack
  • Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area

Exclusion Criteria:

  • Predicted inability to swallow study medication
  • Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
  • Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke

Other protocol defined inclusion/exclusion criteria could apply

Locations

  • UC Davis Health accepting new patients
    Sacramento California 95817 United States
  • Stanford Stroke Center accepting new patients
    Palo Alto California 94304 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
Sign up for this study
ID
NCT03766581
Phase
Phase 2
Study Type
Interventional
Last Updated